JERSEY CITY, N.J., March 08, 2025--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced results from an analysis of the Phase 3 ADORING 3 open-label ...
Organon (OGN) announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA cream, 1% once daily in adults and children 2 years of age and ...
Organon (OGN) reported $1.59 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 0.4%. EPS of $0.90 for the same period compares to $0.88 a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback